Notice for satralizumab (Roche Products Pty Limited)
Active ingredients
satralizumab
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Solution for subcutaneous injection
Indication
Treatment of patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) who are anti aquaporin 4 antibody positive
Therapeutic area
Haematology